Medical network - July 25, in the first half of this year, domestic has multiple import drugs appeared, among them, the DPP 4 inhibitors imported compound was added two new products, respectively is: boehringer ingelheim, Craig dean metformin (2017/3/22) and astrazeneca's Glenn dean metformin zyban (2017/5/18). Approval of the import compound DPP - 4 inhibitor will promote the domestic market shuffle.
At present, 9 DPP - 4 inhibitor products are listed in China. Among them, the unilateral has 5: respectively is west Glenn dean Glenn dean (jie novy), sand (onglyza), d Glenn dean pills (d), lige column dean (Mr Stewart downing, agger column dean piece of the (hin); Compound has four: metformin respectively are west Glenn dean (Czech norda), d Glenn dean metformin (combined), metformin, Craig dean double ning (Europe), the sand Glenn dean metformin zyban (AnLiGe). All nine products are imported products of transnational enterprises, and domestic enterprises have not yet entered the market.
The DPP - 4 inhibitors have been used in the global blockbuster drugs
Diabetes has become one of the world's worst public health problems, with 415 million adults worldwide, according to the international diabetes federation in 2015. China has the world's largest number of diabetes patients, with about 110 million people. Our country diabetes consumption group is large, gradually appear younger trend.
In recent years, with the emergence of new type of hypoglycotics, the market for diabetes drugs has shown a rapid growth trend, which currently ranks second only to cancer drug sales in the world.
According to the 2016 global sales Top 50 pharmaceutical statistics, the Top 50 product sales totaled $210 billion, with the Top 50 entering the threshold for more than $2.1 billion in sales. Among them, there are seven diabetes products into the top 50, insulin, west Glenn dean, lalu peptide, door winter, lai insulin, insulin, insulin west Glenn dean/metformin, this 7 products in total sales of $23.39 billion. Among them, the DPP -4 inhibitor has two products in the top 50, with the sales volume of the company in the top 50, respectively. Sieglitin/metformin has a sales of $22.01 billion, ranking 48th, and dp-4 inhibitors have gained a foothold in the world's best-selling drugs.
Currently, the major drugs in the global diabetes mainstream include insulin, DPP - 4 inhibitors, glp-1 receptor agonists, sglt-2 inhibitors, and traditional oral hypoglycemic drugs. The global market for diabetes drugs is dominated by the pharmaceutical giants such as Merck, novo nord, sanofi and eli lilly. The market concentration is very high. The main products are: west glitine, segal and metformin; The lilarupeptides, mentodine insulin, and ground insulin of novo nord; Sanofi's insulin; Lai lai insulin.
Siglidine and compound preparations are global
According to global drug data statistics, in 2016 the global DPP 4 inhibitors, the main products are: MSD west Glenn dean and compound west Glenn dean metformin, novartis vader column dean, bristol-myers squibb, sandy Craig dean Glenn and compound sand dean of metformin, lilly Glenn. Among them, the most outstanding products were sigredine and the compound zegrlidine metformin. In 2011, sales of these two products exceeded $5 billion, and in 2012-2016, the sales of the two products exceeded $6 billion, which was the highest in the whole dd-4 inhibitor lowering market.
Sieglitin is a new generation of dd-4 inhibitor oral medication developed by Merck and approved by the us FDA in 2006. West Glenn dean opened up a new generation of oral hypoglycemic drugs milestone, the drug and its compound preparations have been listed on the approved hundred countries around the world, because of these two products has become a field of DPP 4 inhibitors, the best-selling products.
From 2008 to 2016, the trend of the sales trend of sigreting and its compound agents in the world, the DPP -4 inhibitor maintained high growth in 2008-2012, and the market was relatively stable in 2013-2016. The compound growth rate was 35.1% in 2008-2013. The growth rate was 34.7% in 2010, 53.8% in 2011 and 14.9% in 2012, compared with 2.4% in 2013. The market began to slow in 2013, and in 2016 it fell slightly.
In 2016, west Glenn with sales of $3.91 billion, west Glenn compound metformin sales were $2.2 billion, these two products occupy global DPP - 4 inhibitor drugs more than 65.8% of the market, the rapid growth in recent years, in varying degrees, and so did the global diabetes overall market growth.
The first three products in the domestic market
As a newer drug to treat diabetes, the pd-4 inhibitor is currently mainly used for treatment of type 2 diabetes. This kind of products with its good safety and tolerability, the advantages of the low incidence of hypoglycemia, but oral, gradually been fully recognized in the domestic and international clinical guidelines, treatment status, gradually become one of the main hypoglycemic drug market.
According to data from domestic sample hospital, the sales volume of DPP -4 inhibitor in the sample hospital in 2016 was 170 million yuan. Of the total sales, the sales of siegliting were 61.61 million yuan, $45.98 million in the sales of chargleting, $27.98 million for wegleting, 11.9 million yuan for liguliting, and 4.38 million yuan for agritin sales. Sigretting/metformin sales were $13.55 million, metformin/viglitine sales of 350,000 yuan. The top three products, sigreding, shakel, and wegliptine, were at 20.9%, 19.8% and 16.6%, respectively. Notably, seguliting/metformin was 214.6 percent over the same period. Segregine and shaglitin have a larger share of the d-4 inhibitor market, and other products have maintained a higher rate of growth over the same period.
In 2016, involving the DPP 4 inhibitors have seven production enterprises, all enterprises with foreign investment, among them, the MSD west Glenn dean "jie novy" occupies 37.3% market share, bristol-myers squibb, sandy Craig dean "onglyza" 28.0% share, novartis d Glenn dean "good music" accounted for 16.9% market share, sales in the first three product hao took 82.0% of the market, the other four products west Glenn dean/metformin, Glenn dean, agger column dean, metformin d Glenn dean occupies 18.0% market share. In recent 3 years, the west imports Glenn, the sand Glenn dean, statins d Glenn dean three products in the domestic market has a good performance, the current domestic market is still in its early DPP 4 inhibitors, is growing rapidly.
Health access helps the market
This year on March 21, people club department released the 2017 edition of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue, high-profile DPP 4 inhibitors have five products to enter the new health insurance directory, respectively are west Glenn dean, agger column dean, lige column, the sand Glenn dean, statins d Glenn dean oral interpretation of the dosage form, health care category b, limit second-line drugs.
At present, China has a high incidence of diabetes, and the market for diabetes drugs is huge. The five newly added pd-4 inhibitors of diabetes oral medicine in the health care catalogue are exclusive varieties, and the market has always been occupied by foreign enterprises. The future has a large space for improvement.
Draw lessons from past years after entering health care products will be continuously increment, DPP 4 inhibitors into the national health insurance directory, soon will also promote the acceleration of drug market in quantity, the future will provide clinicians with more choices, and benefit more patients with type 2 diabetes. With the increasing number of new diabetes drugs in China, the reshuffle of the market pattern of diabetes treatment will be accelerated.
It's worth noting that in April 2016, the FDA issued new security warning messages for two ddd-4 inhibitors, such as salgulidin and agletin. The FDA warned that Glenn dean and agger column containing sand dean of oral medications may increase the risk of type 2 diabetes patients with heart failure, especially those with a history of heart disease and kidney disease in patients with type 2 diabetes.
Summary < < <
The diabetes market has become a competitive place in the global drug market, and domestic enterprises have been developing a boom in drug development. With the advancement of clinical application, the pd-4 inhibitor has become a popular category for many enterprises. Up to now nearly hundred domestic enterprises put forward the application for registration of DPP 4 inhibitors, DPP 4 inhibitors such new oral medications are emerged on the market, although the DPP 4 inhibitors market advantage is very obvious, but if you want to be diabetes remains to be the market mainstream products to temper. |
